May 30, 2017, Vancouver, B.C. – Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) is pleased to announce that Cannevert Therapeutic Ltd.’s development of its medicinal cannabis pipeline has expanded to include anti-emesis (anti-nausea/vomiting) therapies.

Veritas’ mission, through its research arm Cannevert Therapeutics LTD., has been to identify and develop the most effective proprietary cannabis strains for pain, emesis and PTSD through a scientific approach, that allows the Company to provide doctors and patients with comprehensive evidence of efficacy to provide confidence in prescribing and using these proprietary strains.

Dr. Lui Franciosi states, “thus far, we have screened numerous strains through pharmacological assays for pain and specifically cancer pain, where the efficacy of these strains are concurrently screened against the chemical composition of strains, allowing us to decipher which cannabinoids and chemicals are important in the therapeutic effect and their potential synergetic interaction in their therapeutic effects. For the past six months, we have been fully engaged in expanding the screening for anti-emesis strains through pharmacological assays (animal testing) and chemical assays, and we have already identified several promising strains.”

As previously mentioned, the Cannevert team has identified specific cannabis strains in its pharmacological experiments that indicate potential therapeutic benefits. They have been reproducing these experiments in the laboratory to verify these observations alongside standard clinical drugs, as well as, preparing provisional patent applications to protect company’s intellectual property. Veritas is now focused on sourcing potential clinical research organizations around the world that can immediately evaluate therapeutic efficacy with cancer patients undergoing chemotherapy who are also experiencing therapy-related nausea and vomiting.

About Veritas Pharma Inc.

Veritas Pharma Inc. is an emerging-stage pharmaceutical and IP development company, who, through Cannevert Therapeutics Ltd. (CTL), is advancing the science behind medical cannabis. It is the Company aim, through its investment in CTL, to develop the most effective strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support health claims. CTL’s unique value proposition uses a low-cost research and development model to help drive shareholder value, and speed-to-market. Veritas’ investment in CTL is led by strong management team, bringing together veteran academic pharmacologists, anesthetists & chemists. The company’s commercial mission is to patent protect CTL’s IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion dollar global markets.

Veritas Pharma Inc. is a publicly traded company which trades in three countries including Canada, on the Canadian Stock Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on the Frankfurt exchange under the ticker 2VP.

For more information, please visit our website:

On behalf of the Board of Directors; Veritas Pharma Inc.
Dr. Lui Franciosi
Chief Executive Officer

Further information about the Company is available on our website at  or under our profile on SEDAR at  and on the CSE website at

Investor and Public Relations Contact
Veritas Pharma Inc.
Sam Eskandari
Telephone: +1.416.918.6785
Email: [email protected]

The CSE has not reviewed, nor approved or disapproved the content of this press release.

The Veritas Newsletter

Enter your email to receive news alerts and updates from Veritas Pharma.

You have Successfully Subscribed!